DSY DASSAULT SYSTEMES SA

Dassault Systèmes Partners with Sanofi to Optimize Tech Transfer and Industrialization at Its Future “EVolutive Facilities”

(Euronext Paris: FR0014003TT8, DSY.PA) and today announced their partnership to optimize “EVolutive Facility” production at Sanofi’s in France and Singapore. The partnership, which expands their long-standing collaboration in life sciences and healthcare, will leverage virtual twin experiences to enable agile and flexible operations that advance Sanofi’s ambition to secure its product portfolio.

Sanofi will use Dassault Systèmes’ “” industry solution experience based on the 3DEXPERIENCE platform to design, implement, qualify and operate modular production lines at the two “EVolutive Facilities.” These will rely on single-use technology and mobile equipment to manufacture up to four products simultaneously and sustainably by selecting the most advanced technologies to reduce their energy consumption. The platform provides a virtual environment for collaborative innovation and end-to-end data management across the life cycle. Sanofi can experience the manufacturing systems under development and their operation virtually and optimize scale up and industrialization processes before deploying them.

“We want to improve people’s lives by giving them faster access to vaccines and treatments while minimizing the environmental impacts of our activities,” said Ana Alves, EVolutive Facility Global Project Head & Site Head of Neuville sur Saone, Sanofi. “Dassault Systèmes delivers the technology we need to accelerate the introduction of new products in the facility by supporting the collaborative works of our teams and by strengthening the standardization of designs and models. It will also bring capabilities to reach our objective to produce several products in the EVF in an optimized schedule, thanks to the digital twin. Then, the 3DEXPERIENCE platform will help us to address the complexity of the product lifecycle management in a highly regulated environment and for the benefit of our patients.”

Pharmaceutical manufacturers must qualify facilities, equipment and processes before production to ensure safety and quality. This can take weeks or months depending on the equipment configurations and process parameters for different product recipes. Virtual twins enable manufacturers to standardize modules, reduce this timeframe, and boost their ability to quickly and massively produce crucial therapies.

With a virtual twin, Sanofi can visualize and simulate the recipe, equipment and consumables that a particular process requires, as well as the flow and activity of the modules and operators in the “ballroom” – a flexible and adaptable area that enables manufacturers to quickly switch between processes. Sanofi can add, remove and replace functional elements and process steps as needed in a seamless way, and reconfigure the production lines for a fast changeover from one product to another one. It can also accelerate the main activities of the life cycle of new modules, processes and facilities more quickly and catalog them into its product life cycle management for reuse and faster product changeover.

“The pandemic made it clear: BioPharmas must be able to maximize efficiency and quickly provide high-quality, innovative therapeutics to patients worldwide,” said Claire Biot, Vice President, Life Sciences & Healthcare Industry, Dassault Systèmes. “Sanofi is responding to this challenge with next generation modular manufacturing that can transform the speed at which products reach patients. Thanks to the 3DEXPERIENCE platform, Sanofi will implement new products right the first time, with faster production ramp-ups and concurrent process production for built-in flexibility. Ergonomics on the shop floor can be simulated and improved.”

FOR MORE INFORMATION

Sanofi’s “EVolutive Facilities” in France and Singapore:

Dassault Systèmes’ industry solution experiences for the Life Science & Healthcare Industry:

Dassault Systèmes’ 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions:

SHARE THIS ON TWITTER

New partnership between @sanofi @Dassault3DS aims to optimize production at Sanofi’s future facilities in France and Singapore #3DEXPERIENCE

Connect with Dassault Systèmes on

| | |

ABOUT DASSAULT SYSTÈMES

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit

ABOUT SANOFI

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

EN
26/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DASSAULT SYSTEMES SA

 PRESS RELEASE

Caidya Reimagines Next Generation Clinical Trial Innovation and Study ...

Caidya Reimagines Next Generation Clinical Trial Innovation and Study Delivery with Medidata AI-Powered Experiences New Experiences solutions, including Medidata CTMS and Medidata Clinical Data Studio, enable Caidya to enhance its white-glove service to better serve customers NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that , a leading global, mid-sized clinical research organization (CRO), has invested in additional solutions within the , including and . With Med...

 PRESS RELEASE

National Cancer Institute Broadens Partnership with Medidata to Bring ...

National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations The Medidata Data Experience offering will enable the National Cancer Institute Lead Protocol Organizations to expedite the development of life-saving medicines for patients NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that and , both integral components of the , will be available to a select set of Lead Protocol O...

 PRESS RELEASE

Medidata Expands Collaboration with CTI Clinical Trial and Consulting,...

Medidata Expands Collaboration with CTI Clinical Trial and Consulting, Shaping a New Era of Patient-Centric Studies Medidata Patient Experience will accelerate CTI’s treatments for patients with oncology, metabolic, cardiovascular, central nervous system, and immune conditions NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and (CTI), a global leader in research services for advanced therapies, have expanded their 12-year relationship. The new agreement places the and its essential,...

 PRESS RELEASE

Medidata Unveils Next-Generation Patient Consent Innovations, Designed...

Medidata Unveils Next-Generation Patient Consent Innovations, Designed in Partnership with Clinicians and Patient Advocates Medidata Consent, a key part of the , expedites study start-up, reduces configuration complexity, and improves patient enrollment NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced notable advances to , its industry-proven electronic informed consent technology. Delivered through the , this modern solution reimagines patient consent in clinical trial...

 PRESS RELEASE

UPDATE - Medidata Extends Collaboration with Sanofi for the Developmen...

UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration with Sanofi in clinical research. As part of this extension Sanofi will use the , building on the organizations’ v...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch